title: The interpretation of secondary blood markers can get hazardous in case of a discontinuous rhEPO treatment.
authors.affiliation: Laboratoire Suisse d'Analyse du Dopage, Institut Universitaire de Médecine Légale, Rue du Bugnon 21, 1005 Lausanne, Switzerland. neil.robinson@inst.hospvd.ch
authors.forename: Neil
authors.initials: N
authors.lastname: Robinson
authors.forename: Martial
authors.initials: M
authors.lastname: Saugy
authors.forename: Thierry
authors.initials: T
authors.lastname: Buclin
authors.forename: Gérald
authors.initials: G
authors.lastname: Gremion
authors.forename: Patrice
authors.initials: P
authors.lastname: Mangin
mesh_terms: D015415:Biomarkers / Q000097:blood; D004300:Doping in Sports; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood; D006400:Hematocrit; D006801:Humans; D007501:Iron / Q000008:administration & dosage / Q000097:blood; D010507:Periodicity; D011994:Recombinant Proteins; D015813:Substance Abuse Detection / Q000379:methods*
chemical_list: D015415:Biomarkers; D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron